ChromaDex Loses Ruling on Patents in Case Over Elysium’s Basis

Two patents licensed exclusively to ChromaDex were invalidated in a win for Elysium Health, whose Basis dietary supplement ChromaDex had accused of infringing the patents related to vitamin B3 supplements.

• U.S. Judge Colm Connolly on Tuesday granted Elysium’s request to find the patents invalid and canceled the jury trial scheduled to start Sept. 27, according to order issued in federal court in Wilmington, Delaware
  • Connolly will issue an opinion “on a later date,” order says
• Shares of ChromaDex fell 8.3% at 12:21 p.m. in New York on Wednesday, after slumping as much as 26%
• ChromaDex and Dartmouth College, ...